Cerebrospinal fluid monoamine metabolism in a case of neuroleptic malignant syndrome improved by electroconvulsive therapy.
Nisijima
K
K
Oyafuso
K
K
Shimada
T
T
Hosino
H
H
Ishiguro
T
T
D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy; D004565:Electroconvulsive Therapy; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid*; D008803:Mianserin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000134:cerebrospinal fluid / Q000628:therapy*; D009460:Neurologic Examination / Q000187:drug effects; D012008:Recurrence; D013469:Sulpiride / Q000009:adverse effects / Q000627:therapeutic use
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D008803:Mianserin; D006897:Hydroxyindoleacetic Acid; C050605:setiptiline; D013469:Sulpiride; D006719:Homovanillic Acid